Castrucci William A, Knisely Jonathan P S
Department of Therapeutic Radiology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut 06520-8040, USA.
Cancer J. 2008 May-Jun;14(3):138-46. doi: 10.1097/PPO.0b013e318172d6e1.
Brain metastases occur frequently and are a significant threat to the quality of life in patients with small cell lung carcinoma. The primary treatment modality has historically been whole brain radiation, which can provide a moderate extension of life and improvement in neurologic symptoms. Despite increasing interest in the use of alternative therapeutic agents-primarily chemotherapy-these have yet to be demonstrated to be superior to radiation in management of brain metastasis. Prophylactic cranial irradiation prevents or delays the occurrence of brain metastases in patients with small cell lung carcinoma. Until recently, this benefit has been thought to be primarily restricted to a minority of patients with limited stage disease. A large European trial, however, has now shown a survival benefit to the use of prophylactic cranial irradiation in patients who have any response to systemic chemotherapy. This finding should significantly shift management practices for this aggressive disease for most patients.
脑转移瘤很常见,对小细胞肺癌患者的生活质量构成重大威胁。传统的主要治疗方式是全脑放疗,它能适度延长生存期并改善神经症状。尽管人们对使用替代治疗药物(主要是化疗)的兴趣日益增加,但在脑转移瘤的治疗中,这些药物尚未被证明优于放疗。预防性颅脑照射可预防或延缓小细胞肺癌患者脑转移瘤的发生。直到最近,人们一直认为这种益处主要局限于少数局限期疾病患者。然而,一项大型欧洲试验现已表明,对全身化疗有任何反应的患者使用预防性颅脑照射可带来生存益处。这一发现应会显著改变大多数此类侵袭性疾病患者的治疗方式。